CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects

Life Sciences

Volumn 74, Issue 7, 2004, Pages 827-834

  Soga, Yoshihiko ^a   Nishimura, Fusanori ^a   Ohtsuka, Yoko ^a   Araki, Hiroaki ^b,c,d   Iwamoto, Yoshihiro ^a   Naruishi, Hisa ^a   Shiomi, Nobuyuki ^a   Kobayashi, Yoshitomo ^c   Takashiba, Shogo ^a   Shimizu, Kenji ^a   Gomita, Yutaka ^b   Oka, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Sekizen Hospital   (Japan)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome P450; Gingival overgrowth; Phenytoin; Single nucleotide polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 2C9 GENE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; EPILEPSY; FEMALE; GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GINGIVA OVERGROWTH; HUMAN; LONG TERM CARE; MALE; PREDICTION;

EID: 10744228301     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.07.018     Document Type: Article

References (15)

1. Angelopoulos A.P., Goaz P.W. Incidence of dephenylhydantoin gingival hyperplasia. Oral Surgery. 34(6):1972;898-906.
2. Goldstein J.A., Faletto M.B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J.L., Lasker J.M., Ghanayem B.I. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 33(7):1994;1743-1752.
3. Hashimoto Y., Otsuki Y., Odani A., Takano M., Hattori H., Furusho K., Iui K. Effect of CYP2C polymorphisms on the phamacokinetics of phenytoin in Japanese patients with epilepsy. Biology and Pharmacology Bulletins. 19(8):1996;1103-1105.
4. Kubota T., Chiba K., Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clinical and Pharmacological Therapies. 60(6):1996;661-666.
5. Kupfer A., Preisig R. Phamacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology. 26(6):1984;753-759.
6. Mamiya K., Ieiri I., Shimamoto J., Yukawa E., Imai J., Ninomiya H., Yamada H., Otsubo K., Higuchi S., Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 39(12):1998;1317-1323.
7. Nakamura K., Goto F., Ray W.A., McAllister C.B., Jacqz E., Wilkinson G.R., Branch R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics. 38(4):1985;402-408.
8. Nishimura F., Naruishi H., Naruishi K., Yamada T., Sasaki J., Peters C., Uchiyama Y., Murayama Y. Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth. A study with cathepsin-L-deficient mice. American Journal of Pathology. 161(12):2002;2047- 2052.
9. Odani A., Hashimoto Y., Otsuki Y., Uwai Y., Hattori H., Furusho K., Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clinical and Pharmacological Therapies. 62(3):1997;287-292.
10. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-Mephenytoin metabolism in humans. Journal of Biological Chemistry. 269(22):1994;15419-15422.
11. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Phamacogenetics. 6(5):1996;429-439.
12. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6(4):1996;341-349.
13. Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., Birkett D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochemical Biophysical Research Communications. 175(3):1991;1112-1118.
14. Yamada H., Nishimura F., Naruishi K., Chou H.H., Takashiba S., Albright G.M., Nares S., Iacopino A.M., Murayama Y. Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. Journal of Periodontology. 71(6):2000;955-960.
15. Yamada H., Nishimura F., Furuno K., Naruishi K., Kobayashi Y., Takashiba S., Murayama Y. Serum phenytoin concentration and IgG antibody titer to periodontal bacteria in patients with phenytoin-induced gingival overgrowth. Journal of the International Academy of Periodontology. 3(2):2001;42-47.